Home Ulinastatin – a newer potential therapeutic option for multiple organ dysfunction syndrome
Article
Licensed
Unlicensed Requires Authentication

Ulinastatin – a newer potential therapeutic option for multiple organ dysfunction syndrome

  • Sarjana S. Atal EMAIL logo and Shubham Atal
Published/Copyright: November 13, 2015
Journal of Basic and Clinical Physiology and Pharmacology
From the journal Journal of Basic and Clinical Physiology and Pharmacology Volume 27 Issue 2

Abstract

Despite significant improvements in medical and surgical management, multiple organ dysfunction syndrome (MODS) or multiple organ failure following conditions such as acute pancreatitis, severe sepsis, and traumatic, hemorrhagic, and endotoxin shocks is still accompanied with a high mortality rate. In light of the crucial role of immunologic derangement recently conceptualized in these conditions, ulinastatin, a urinary trypsin inhibitor, is considered as a potentially beneficial immunomodulator drug for MODS. Mechanisms involving protections against tissue organs and endothelial cell and anti-inflammatory effects by ulinastatin are dependent on the inhibition of polymorphonuclear leukocyte (PMN)-derived elastase, tumor necrosis factor α, and other pro-inflammatory cytokines and interleukins (IL-1, IL-6, and IL-8). Ulinastatin also suppresses the activation of PMN cells, macrophages, and platelets. Derived from these properties, ulinastatin has been investigated as a potential clinical therapy for indications including shock and pancreatitis and approved in Japan and China with ongoing clinical trials around the globe. Off-label potential uses of ulinastatin have been reported in preterm labor and hematological, hepatic, renal, and cardiovascular diseases including vasculitis syndromes such as Kawasaki disease.

Keywords: immunomodulation; multiple organ dysfunction syndrome; sepsis; ulinastatin
Corresponding author: Sarjana S. Atal, Modern Institute of Medical Sciences, Department of Pharmacology, Indore, Madhya Pradesh, India, Phone: +91 731-4209549, +91 9424561049, E-mail:

References

1. Esper AM, Martin GS. Extending international sepsis epidemiology: the impact of organ dysfunction. Crit Care 2009;13:120.10.1186/cc7704Search in Google Scholar

2. Balk RA. Pathogenesis and management of multiple organ dysfunction or failure in severe sepsis and septic shock. Crit Care Clin 2000;16:337–52.10.1016/S0749-0704(05)70113-5Search in Google Scholar

3. Deitch EA, Goodman ER. Prevention of multiple organ failure. Surg Clin North Am 1999;76:1471–88.10.1016/S0039-6109(05)70088-8Search in Google Scholar

4. Matsuda N, Hattori Y. Systemic inflammatory response syndrome (SIRS): molecular pathophysiology and gene therapy. J Pharmacol Sci 2006;101:189–98.10.1254/jphs.CRJ06010XSearch in Google Scholar

5. Murray MJ, Coursin DB. Mutliple organ dysfunction syndrome. Yale J Biol Med 1993;66:501–10.Search in Google Scholar

6. Yealy DM, Kellum JA, Huang DT, Barnato AE, Weissfeld LA, Pike F, et al. A randomized trial of protocol-based care for early septic shock. N Engl J Med 2014;370:1683–93.10.1056/NEJMoa1401602Search in Google Scholar

7. Rice TW. Treatment of severe sepsis: where next? current and future treatment approaches after the introduction of drotrecogin alfa. Vasc Health Risk Manag 2006;2:3–18.10.2147/vhrm.2006.2.1.3Search in Google Scholar

8. Hotchkiss RS, Monneret G, Payen D. Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. Lancet Infect Dis 2013;13:260–8.10.1016/S1473-3099(13)70001-XSearch in Google Scholar

9. Leng Y, Yang SG, Song Y, Zhu X, Yao G. Ulinastatin for acute lung injury and acute respiratory distress syndrome: a systematic review and meta-analysis. World J Crit Care Med 2014;3:34–41.10.5492/wjccm.v3.i1.34Search in Google Scholar PubMed PubMed Central

10. Goris RJ. MODS/SIRS: result of an overwhelming inflammatory response? World J Surg 1996;20:418–21.10.1007/s002689900066Search in Google Scholar PubMed

11. Bone CR, Balk RA, Cerra FB, Dellinger RP, Fien AM, Knaus WA, et al. Definition of sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 1992;101:1644–55.10.1378/chest.101.6.1644Search in Google Scholar PubMed

12. Crea F, Biassucci LM. Innate immune inflammatory response to danger: when, how and why does a friend become a foe? Eur Heart J 2012;33:1434–7.10.1093/eurheartj/ehs033Search in Google Scholar PubMed

13. Yao YM, Redl H, Bahrami S, Schlag G. The inflammatory basis of trauma/shock-associated multiple organ failure. Inflamm Res 1998;47:201–10.10.1007/s000110050318Search in Google Scholar PubMed

14. Cai B, Deitch EA, Ulloa L. Novel insights for systemic inflammation in sepsis and hemorrhage. Mediators Inflamm 2010;2010:642462.10.1155/2010/642462Search in Google Scholar PubMed PubMed Central

15. Wang H, Ma S. The cytokine storm and factors determining the sequence and severity of organ dysfunction in multiple organ dysfunction syndrome. Am J Emerg Med 2008;26:711–5.10.1016/j.ajem.2007.10.031Search in Google Scholar PubMed

16. Aziz M, Jacob A, Yang WL, Matsuda A, Wang P. Current trends in inflammatory and immunomodulatory mediators in sepsis. J Leukoc Biol 2013;93:329–42.10.1189/jlb.0912437Search in Google Scholar PubMed PubMed Central

17. Laffey JG, Boylan JF, Cheng DC. The systemic inflammatory response to cardiac surgery: implications for the anesthesiologist. Anesthesiology 2002;97:215–52.10.1097/00000542-200207000-00030Search in Google Scholar PubMed

18. Iskander KN, Osuchowski MF, Stearns-Kurosawa DJ, Kurosawa S, Stepien D, Valentine C, et al. Sepsis: multiple abnormalities, heterogenous responses and evolving understanding. Physiol Rev 2013;93:1247–88.10.1152/physrev.00037.2012Search in Google Scholar PubMed PubMed Central

19. Yarema TC, Yost S. Low-dose corticosteroids to treat septic shock: a critical literature review. Crit Care Nurse 2011;31:16–26.10.4037/ccn2011551Search in Google Scholar PubMed

20. Peck P. Early initiation of drotecogin alfa may improve survival. Available at: http://www.medscape.com/viewarticle/470592. Accessed: 18 Dec 2014.Search in Google Scholar

21. Cronin L, Cook DJ, Carlet J, Heyland DK, King D, Lansang MA, et al. Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. Crit Care Med 1995;23:1430–9.10.1097/00003246-199508000-00019Search in Google Scholar PubMed

22. Shukla A, Awasthi S. Role of human recombinant activated protein C and low dose corticosteroid therapy in sepsis. Indian J Anaesth 2010;54:496–503.10.4103/0019-5049.72637Search in Google Scholar PubMed PubMed Central

23. Gaillard RC, Turnill D, Sappino P, Muller AF. Tumor necrosis factor alpha inhibits the hormonal response of the pituitary gland to hypothalamic releasing factors. Endocrinology 1990;127:101–6.10.1210/endo-127-1-101Search in Google Scholar PubMed

24. Balk RA. Steroids for septic shock: back from the dead? (Pro). Chest 2003;123:490S–9S.10.1378/chest.123.5_suppl.490SSearch in Google Scholar

25. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008;36:296–327.10.1097/01.CCM.0000298158.12101.41Search in Google Scholar

26. Fisher CJ Jr, Yan SB. Protein C levels as a prognostic indicator of outcome in sepsis and related diseases. Crit Care Med 2000;28:S49–56.10.1097/00003246-200009001-00011Search in Google Scholar

27. Hosac MA. Drotecogin alfa (activated): the first FDA-approved treatment for severe sepsis. Proc (Bayl Univ Med Cent) 2002;15:224–7.10.1080/08998280.2002.11927844Search in Google Scholar

28. Alaniz C. An update of activated protein C (Xigris) in the management of sepsis. P T 2010;35:504–8.Search in Google Scholar

29. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriquez A, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699–709.10.1056/NEJM200103083441001Search in Google Scholar

30. Fries E, Biom AM. Bikunin – not just a plasma proteinase inhibitor. Int J Biochem Cell Biol 2000;32:125–37.10.1016/S1357-2725(99)00125-9Search in Google Scholar

31. Park KH, Lee KH, Kim H, Hwang SO. The anti-inflammatory effects of ulinastatin in trauma patients with hemorrhagic shock. J Korean Med Sci 2010;25:128–34.10.3346/jkms.2010.25.1.128Search in Google Scholar

32. Inoue K, Takano H. Urinary trypsin inhibitor as a therapeutic option for endotoxin-related inflammatory disorders. Expert Opin Investig Drugs 2010;19:513–20.10.1517/13543781003649533Search in Google Scholar

33. Pugia MJ, Valdes R Jr, Jortani SA. Bikunin (urinary trypsin inhibitor): structure, biological relevance and measurement. Adv Clin Chem 2007;44:223–45.10.1016/S0065-2423(07)44007-0Search in Google Scholar

34. Han JI. Urinary trypsin inhibitor: miraculous medicine in many surgical situations? Korean J Anesthesiol 2010;58:325–7.10.4097/kjae.2010.58.4.325Search in Google Scholar PubMed PubMed Central

35. Xu CE, Zhang MY, Zou CW, Guo L. Evaluation of the pharmacological function of ulinastatin in experimental animals. Molecules 2012;17:9070–80.10.3390/molecules17089070Search in Google Scholar PubMed PubMed Central

36. Ulinastatin for injection. U-TrypTM. Available at: http://www.bharatserums.com/product/critical/UTryp%20%28Liquid%29%20Common%20Pack%20Insert%20for%20Domestic.pdf. Accessed: 19 Dec 2014.Search in Google Scholar

37. Jonsson-Berling BM, Ohisson K. Distribution and elimination of intravenously injected urinary trypsin inhibitor. Scan J Clin Lab Invest 1991;51:549–57.10.3109/00365519109104564Search in Google Scholar

38. Yanez JA, Remsberg CM, Sayre CL, Forrest ML, Davies NM. Flip-flop pharmacokinetics: delivering a reversal of disposition: challenges and opportunities during drug development. Ther Deliv 2011;2:643–72.10.4155/tde.11.19Search in Google Scholar

39. Chen H, He MY, Li YM. Treatment of patients with severe sepsis using ulinastatin and thymosin alpha 1: a prospective, randomized, controlled pilot study. Chin Med J (Engl) 2009;122:883–8.Search in Google Scholar

40. Wang N, Lui X, Zheng X, Cao H, Wei G, Zhu Y, et al. Ulinastatin is a novel candidate drug for sepsis and secondary acute lung injury, evidence from an optimized CLP rat model. Int Immunopharmacol 2013;17:799–807.10.1016/j.intimp.2013.09.004Search in Google Scholar

41. Yang Q, Lui X, Lui M, Zhang L, Guan Y. Ulinastatin-mediated protection against zymosan-induced multiple organ dysfunction in rats. Biologicals 2010;38:552–6.10.1016/j.biologicals.2010.05.001Search in Google Scholar

42. Jiang L, Yang L, Zhang M, Fang X, Huang Z, Yang Z, et al. Beneficial effects of ulinastatin on gut barrier function in sepsis. Indian J Med Res 2013;138:904–11.Search in Google Scholar

43. Fang Q, Chen P. A study on clinical efficacy of ulinastatin in severe sepsis patients and its mechanism of action. Chinese J Infec Chemoth 2005;1:13–6.Search in Google Scholar

44. Hong-ying N, Fang Q, Yun-tao Z. Effects of ulinastatin on inflammatory response and curative effect in severe sepsis patients. Chin J Crit Care Med 2008;4:342–4.Search in Google Scholar

45. Moon SW, Lee SW, Hong YS, Park DW, Jang IJ, Yoon YH, et al. The effects of urinary trypsin inhibitor on the outcomes of severe sepsis and septic shock patients. J Korean Soc Emerg Med 2009;20:80–5.Search in Google Scholar

46. Karnad DR, Bhadade R, Verma PK, Moulick ND, Daga MK, Chafekar ND, et al. Intravenous administration of ulinastatin (human urinary trypsin inhibitor) in severe sepsis: a multicenter randomized controlled study. Intens Care Med 2014;40:830–8.10.1007/s00134-014-3278-8Search in Google Scholar

47. Abraham P, Rodrigues J, Moulick N, Dharap S, Chafekar N, Verma PK, et al. Efficacy and safety of intravenous ulinastatin versus placebo along with standard supportive care in subjects with mild or severe acute pancreatitis. J Assoc Physicians India 2013;61:535–8.Search in Google Scholar

48. Tsujino T, Komatsu Y, Isayama H, Hirano K, Sasahira N, Yamamoto N, et al. Ulinastatin for pancreatitis after endoscopic retrograde cholangiopancreatography: a randomized, controlled trial. Clin Gastroenterol Hepatol 2005;3:376–83.10.1016/S1542-3565(04)00671-8Search in Google Scholar

49. Tsujino T, Kawabe T, Omata M. Antiproteases in preventing post-ERCP acute pancreatitis. J Pancreas 2007;8:509–17.Search in Google Scholar

50. Pandol SJ, Saluja AK, Imrie CW, Banks PA. Acute pancreatitis: bench to the bedside. Gastroenterology 2007;132:1127–51.10.1053/j.gastro.2007.01.055Search in Google Scholar PubMed

51. Chen SY, Wang JY. Ulinastatin in the treatment of acute pancreatitis: a multicenter clinical trial. Chin J Dig 2002;3:70–4.10.1046/j.1443-9573.2002.00074_3_2.xSearch in Google Scholar

52. Inamo Y, Okubo T, Wada M, Fuchigami S, Hashimoto K, Fuchigami T, et al. Intravenous ulinastatin therapy for Stevens-Johnson syndrome and toxic epidermal necrolysis in pediatric patients. Three case reports. Int Arch Allergy Immunol 2002;127:89–94.10.1159/000048174Search in Google Scholar PubMed

53. Leng YX, Yang SG, Song YH, Zhu X, Yao GQ. Ulinastatin for acute lung injury and acute respiratory distress syndrome: a systematic review and meta-analysis. World J Crit Care Med 2014;3:34–41.10.5492/wjccm.v3.i1.34Search in Google Scholar PubMed PubMed Central

54. Xu B, Li KP, Shen F, Xiao HQ, Cai WS, Li JL, et al. Ulinastatin reduces cancer recurrence after resection of hepatic metastases from colon cancer by inhibiting MMP-9 activation via the antifibrinolytic pathway. Biomed Res Int 2013;2013:437950.10.1155/2013/437950Search in Google Scholar PubMed PubMed Central

55. Luo J, Sun X, Gao F, Zhao X, Zhong B, Wang H, et al. Effects of ulinastain and docetaxel on breast cancer invasion and expression of uPA, uPAR and ERK. J Exp Clin Cancer Res 2011;30:71.10.1186/1756-9966-30-71Search in Google Scholar PubMed PubMed Central

56. Zhong B, Shen H, Sun X, Wang H, Zhang Y, Sun Z. Additive effects of ulinastatin and docetaxel on growth of breast cancer xenograft in nude mice and expression of PGE2, IL-10 and IL-2 in primary breast cancer cells. Cancer Biother Radiopharm 2012;27:252–8.10.1089/cbr.2011.1105Search in Google Scholar PubMed

57. Matsuda Y, Yunohara N. Effects of urinary trypsin inhibitor in patients at risk for premature labor with a bulging fetal membrane. Fetal Diagn Ther 2002;17:69–74.10.1159/000048011Search in Google Scholar PubMed

58. Park KH, Lee KH, Kim H, Hwang SO. The anti-inflammatory effects of ulinastatin in trauma patients with hemorrhagic shock. J Korean Med Sci 2010;25:128–34.10.3346/jkms.2010.25.1.128Search in Google Scholar PubMed PubMed Central

59. He QL, Zhong F, Ye F, Wei M, Lui WF, Li MN, et al. Does intraoperative ulinastatin improve postoperative clinical outcomes in patients undergoing cardiac surgery: a meta-analysis of randomized controlled trials. Biomed Res Int 2014;2014:630835.10.1155/2014/630835Search in Google Scholar

60. Kanai T, Ishiwata T, Kobayashi T, Sato H, Takizawa M, Kawamura Y, et al. Ulinastatin, a urinary trypsin inhibitor, for the initial treatment of patients with Kawasaki disease: a retrospective study. Circulation 2011;124:2822–8.10.1161/CIRCULATIONAHA.111.028423Search in Google Scholar PubMed

Received: 2015-1-8
Accepted: 2015-8-22
Published Online: 2015-11-13
Published in Print: 2016-3-1

©2016 by De Gruyter

Articles in the same Issue

  1. Frontmatter
  2. Review
  3. Ulinastatin – a newer potential therapeutic option for multiple organ dysfunction syndrome
  4. Behavior and Neuroprotection
  5. Amitriptyline and phenytoin prevents memory deficit in sciatic nerve ligation model of neuropathic pain
  6. Anti-nociceptive activity of a few structurally related trimethoxy flavones and possible mechanisms involved
  7. Oxidative Stress
  8. A mechanism-based pharmacological evaluation of efficacy of Flacourtia indica in management of dyslipidemia and oxidative stress in hyperlipidemic rats
  9. Aqueous extracts of avocado pear (Persea americana Mill.) leaves and seeds exhibit anti-cholinesterases and antioxidant activities in vitro
  10. Biochemical effects of lead exposure on oxidative stress and antioxidant status of battery manufacturing workers of Western Maharashtra, India
  11. Hematological Profile
  12. Phenotypic variations in osmotic lysis of Sahel goat erythrocytes in non-ionic glucose media
  13. Infection
  14. Prevalence, risk factors and antimicrobial susceptibility pattern of extended spectrum β-lactamase-producing bacteria in a tertiary care hospital
  15. Phytotherapy
  16. Phytochemical, sub-acute toxicity, and antibacterial evaluation of Cordia sebestena leaf extracts
  17. Short Communication
  18. Leaching from the stratum corneum does not explain the previously reported elevated potassium ion concentration in sweat
https://doi.org/10.1515/jbcpp-2015-0003
Keywords for this article
immunomodulation; multiple organ dysfunction syndrome; sepsis; ulinastatin

Articles in the same Issue

  1. Frontmatter
  2. Review
  3. Ulinastatin – a newer potential therapeutic option for multiple organ dysfunction syndrome
  4. Behavior and Neuroprotection
  5. Amitriptyline and phenytoin prevents memory deficit in sciatic nerve ligation model of neuropathic pain
  6. Anti-nociceptive activity of a few structurally related trimethoxy flavones and possible mechanisms involved
  7. Oxidative Stress
  8. A mechanism-based pharmacological evaluation of efficacy of Flacourtia indica in management of dyslipidemia and oxidative stress in hyperlipidemic rats
  9. Aqueous extracts of avocado pear (Persea americana Mill.) leaves and seeds exhibit anti-cholinesterases and antioxidant activities in vitro
  10. Biochemical effects of lead exposure on oxidative stress and antioxidant status of battery manufacturing workers of Western Maharashtra, India
  11. Hematological Profile
  12. Phenotypic variations in osmotic lysis of Sahel goat erythrocytes in non-ionic glucose media
  13. Infection
  14. Prevalence, risk factors and antimicrobial susceptibility pattern of extended spectrum β-lactamase-producing bacteria in a tertiary care hospital
  15. Phytotherapy
  16. Phytochemical, sub-acute toxicity, and antibacterial evaluation of Cordia sebestena leaf extracts
  17. Short Communication
  18. Leaching from the stratum corneum does not explain the previously reported elevated potassium ion concentration in sweat
Sign up now to receive a 20% welcome discount
Institutional Access
How does access work?
Have an idea on how to improve our website?
Please write us.
© 2025 De Gruyter Brill
Downloaded on 7.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/jbcpp-2015-0003/html
Scroll to top button